KabirModyMD

Oncology • Jacksonville, FL

Gastrointestinal Cancer, Complementary and Integrative

Assistant Professor of Medicine and Consultant Vice Chair, Division of Hematology and Oncology

Join to view full profile

Dr. Mody is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mody's full profile

Already have an account?

Office
4500 San Pablo Rd S
Jacksonville, FL 32224
Phone+1 904-953-2000

Summary

Dr Mody is a GI Oncologist specializing in the care of patients with liver cancers. His research is focused upon immunotherapy and novel drug development for these malignancies. Additionally, his research investigates the use of circulating tumor DNA in the diagnosis and management of hepatobiliary cancers.

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2004 - 2007
St. George's University School of MedicineClass of 2004
Columbia University College of Physicians & SurgeonsMS, Human Nutrition, 1999 - 2000

Certifications & Licensure

FL State Medical License 2014 - 2024
CT State Medical License 2008 - 2016
MA State Medical License 2007 - 2010

Clinical Trials

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2014 Jul 31
Completed
Phase 1, Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Start of enrollment: 2017 Sep 27
Recruiting
Phase 2

Publications & Presentations

PubMed

(HER2) amplifications and co-occurringalterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition.
Afsaneh Barzi, Caroline M Weipert, Carin R Espenschied, Victoria M Raymond, Andrea Wang-Gillam
Frontiers in Oncology. 2024-01-01
6 citations
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, Stephen L Chan, Robin Kate Kelley
Future Oncology. 2023-12-01
2 citations
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.
Leontios Pappas, Islam Baiev, Stephanie Reyes, Andrea Grace Bocobo, Apurva Jain
JCO Precision Oncology. 2023-08-01

Journal Articles

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Mohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology

Lectures

A landscape of circulating tumor DNA in esophageal adenocarcinoma and squamous cell carcinoma.
2019 ASCO Annual Meeting - 6/1/2019
Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to Its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific AdvisorMay 13th, 2022
Can HCC Be Caught Early Using ctDNA?August 22nd, 2019
Alex Trebek's Fight: Why Is Pancreas Cancer Such a Beast?May 2nd, 2019
Join now to see all

Committees

Co-Chair, Mayo Clinic Cancer Center Hepatobiliary Malignancies Disease Group 2017 - Present

Professional Memberships

External Links

Mayo Websitehttp://www.mayoclinic.org/biographies/mody-kabir-m-d/bio-20097397